Welcome to our dedicated page for Collegium Pharmaceutical news (Ticker: COLL), a resource for investors and traders seeking the latest updates and insights on Collegium Pharmaceutical stock.
About Collegium Pharmaceutical Inc.
Collegium Pharmaceutical Inc. (Nasdaq: COLL) is a leading specialty pharmaceutical company committed to improving the lives of patients living with chronic pain and other serious medical conditions. Headquartered in Stoughton, Massachusetts, the company leverages its proprietary DETERx® technology platform to develop and commercialize next-generation, abuse-deterrent medications. Collegium's innovative approach addresses the growing public health concerns surrounding the misuse and abuse of prescription drugs, particularly opioids, while maintaining efficacy for patients who require long-term pain management solutions.
Core Business and Product Portfolio
At the heart of Collegium’s operations is its portfolio of abuse-deterrent medications designed to mitigate risks associated with non-medical use. The company’s flagship product, Xtampza ER®, is an extended-release, oral formulation of oxycodone that employs DETERx® technology to maintain its safety and efficacy profile even when subjected to physical manipulation such as crushing or dissolving. Collegium also markets the Nucynta® franchise, which includes both immediate-release and extended-release formulations of tapentadol, used for managing acute and chronic pain.
In 2024, Collegium expanded its portfolio through the acquisition of Ironshore Therapeutics, adding Jornay PM®, a unique evening-dosed ADHD medication, to its offerings. This strategic move established the company’s presence in the growing neuropsychiatry market, diversifying its revenue streams and positioning it for long-term growth.
Technological Innovation: The DETERx® Platform
Collegium’s proprietary DETERx® technology is a cornerstone of its product development strategy. This platform enables the creation of extended-release formulations that are resistant to common forms of abuse, such as chewing, crushing, and dissolving. By integrating this technology into its medications, Collegium addresses two critical needs: providing effective pain relief for patients and reducing the potential for misuse and abuse. The DETERx® platform is protected by a robust portfolio of U.S. and international patents, underscoring Collegium’s commitment to innovation and intellectual property protection.
Strategic Growth and Market Position
Collegium has established itself as a key player in the specialty pharmaceutical industry through a combination of innovation, strategic acquisitions, and disciplined capital deployment. The company’s focus on responsible pain management has earned it a strong reputation among healthcare providers and patients alike. Its recent acquisition of Ironshore Therapeutics not only diversifies its product portfolio but also enhances its market presence in the neuropsychiatry segment.
With a strong financial foundation and a commitment to operational excellence, Collegium is well-positioned to navigate the challenges of a highly regulated industry. The company continues to invest in research and development, aiming to expand its portfolio and address unmet medical needs in both pain management and neuropsychiatry.
Commitment to Responsible Pain Management
Collegium is dedicated to advancing science-based solutions for pain management while prioritizing patient safety. The company actively engages with healthcare providers, policymakers, and the broader medical community to promote the responsible use of opioid medications. By combining innovative technology with a patient-centered approach, Collegium aims to set new standards in the treatment of chronic pain and other serious medical conditions.
Conclusion
Collegium Pharmaceutical Inc. exemplifies the integration of innovation, responsibility, and strategic growth in the pharmaceutical industry. Through its proprietary DETERx® technology, diverse product portfolio, and commitment to addressing critical public health challenges, the company continues to make meaningful contributions to the healthcare landscape. As it expands into new therapeutic areas like neuropsychiatry, Collegium remains focused on its mission to improve patient outcomes and create long-term value for stakeholders.
Collegium Pharmaceutical (Nasdaq: COLL) reported record net revenue of $129.6 million for Q4 2022 and $463.9 million for FY 2022, compared to $27.4 million and $276.9 million respectively in the previous year. The company exited 2022 with a cash balance of $173.7 million and reaffirmed its 2023 guidance, projecting product revenues between $565 million and $580 million. Collegium implemented strategic initiatives, including acquiring BDSI, achieving $85 million in annual synergies, and resolving all 27 opioid-related lawsuits. The company also initiated a $100 million share repurchase program.
Collegium Pharmaceutical (Nasdaq: COLL) has released its inaugural Environmental, Social and Governance (ESG) report, showcasing its commitment to ethical business practices. Highlights from 2022 include initiatives in corporate governance, Diversity, Equity and Inclusion (DEI), and corporate social responsibility, with over $350,000 donated to STEM initiatives. Collegium aims to reduce environmental impacts through various strategies. CEO Joe Ciaffoni emphasized the company’s dedication to ethical standards, community involvement, and shareholder value as it anticipates growth in 2023.
Collegium Pharmaceutical, Inc. (Nasdaq: COLL) has announced the pricing of a private offering of $210 million in 2.875% convertible senior notes due 2029, up from a previously projected $175 million. The notes are expected to settle on February 10, 2023. The initial conversion price is approximately $36.56 per share, which represents a premium of about 30% over the last stock price of $28.12 on February 7, 2023. The net proceeds are estimated at $203.2 million, aimed at repurchasing $117.4 million of 2026 notes and for general corporate purposes. The offering includes options for initial purchasers to buy an additional $31.5 million of notes.
Collegium Pharmaceutical (Nasdaq: COLL) plans to offer $175 million in convertible senior notes due 2029. The offering is private, intended for qualified institutional buyers, with an additional $26.25 million option for initial purchasers. The notes will accrue interest and can be converted into cash or common stock. Collegium aims to use proceeds to repurchase part of its 2026 Convertible Senior Notes and for general corporate purposes, including working capital and business development. The company has not set specific uses beyond the repurchase of 2026 notes and has no current acquisition agreements.
Collegium Pharmaceutical (Nasdaq: COLL) reported preliminary financial results for Q4 and FY 2022, estimating product revenues of $460.0-$462.5 million for the year and $125.7-$128.2 million for Q4. GAAP operating expenses are projected between $176.5-$181.5 million for the year and $38.4-$43.4 million for the fourth quarter. Adjusted EBITDA is expected to be $261.5-$264.0 million for the year and $71.9-$74.4 million for Q4. The company announced its final results will be disclosed on February 23, 2023, after market close. These results exceed the high-end of their previously issued earnings guidance for 2022.
Collegium Pharmaceutical (Nasdaq: COLL) has announced its financial guidance for 2023, projecting net product revenues between $565 million and $580 million. Adjusted operating expenses are expected to range from $135 million to $145 million, while adjusted EBITDA is forecasted to be between $355 million and $370 million. Notably, the board has authorized a $100 million share repurchase program following a $19.1 million return to shareholders in 2022. The Federal Circuit upheld critical patents for Belbuca, ensuring market exclusivity until 2032.
Collegium Pharmaceutical, Inc. (Nasdaq: COLL) announced that the Federal Circuit upheld the validity of certain patents for Belbuca, blocking ANDA filer Alvogen from entering the market until 2032. The ruling confirms the strength of the company’s patents, including the '866 patent expiring in 2027 and the '539 patent set to expire in 2032. Alvogen conceded infringement on all claims, benefitting Collegium by ensuring Belbuca remains exclusively marketed until the patents expire.
Collegium Pharmaceutical (Nasdaq: COLL) announced participation in the Piper Sandler 34th Annual Healthcare Conference in New York from November 29 to December 1, 2022. Management will engage in a fireside chat on November 30, 2022, at 1:30 p.m. ET. The discussion will be webcast live and accessible via the Investors section of Collegium's website, with a replay available for 90 days post-event. Collegium is dedicated to enhancing the lives of individuals with serious medical conditions, headquartered in Stoughton, Massachusetts.
Collegium Pharmaceutical reported record net revenue of $127.0 million for Q3 2022, up from $78.8 million in Q3 2021. The company successfully renegotiated contracts for Xtampza® ER, achieving a gross-to-net less than 65% starting January 2023. Collegium returned $10 million to shareholders through repurchases. The updated full-year guidance estimates total product revenues between $455.0 and $465.0 million and adjusted EBITDA from $250.0 to $255.0 million. The company exited Q3 with $134.1 million in cash, highlighting strong operational performance.
Collegium Pharmaceutical, Inc. (NASDAQ: COLL) is set to report its third quarter 2022 financial results on November 3, 2022, after market close. A live conference call will follow at 4:30 p.m. ET, accessible via telephone or webcast. Collegium continues to focus on its commitment to improving the lives of those with serious medical conditions, based in Stoughton, Massachusetts. For further details, listeners can access the webcast on the company’s website shortly after the event.
FAQ
What is the current stock price of Collegium Pharmaceutical (COLL)?
What is the market cap of Collegium Pharmaceutical (COLL)?
What does Collegium Pharmaceutical Inc. specialize in?
What is the DETERx® technology platform?
What are Collegium’s key products?
How does Collegium address opioid misuse and abuse?
What was the significance of the Ironshore Therapeutics acquisition?
Where is Collegium Pharmaceutical headquartered?
How does Collegium differentiate itself in the pharmaceutical industry?
What markets does Collegium operate in?
